Shares of Solar Pharmaceutical Industries fell by over 4 per cent in morning commerce on Tuesday a day after the corporate stated its consolidated web loss stood at Rs 2,277 crore for the fourth quarter ended March 2022, primarily on account of a one-time distinctive loss.
The corporate’s inventory declined 4.12 per cent to Rs 851.50 on the BSE.
On the NSE, it tumbled 4.17 per cent to Rs 851.20 apiece.
The Mumbai-based drug main on Monday reported a web revenue of Rs 894 crore within the January-March interval of 2020-21.
Consolidated gross sales from operations stood at Rs 9,386 crore within the fourth quarter.
The corporate had reported gross sales from operations at Rs 8,464 crore within the year-ago interval.
Throughout the interval beneath assessment, the corporate stated it incurred a one-time price of Rs 56.35 crore for restructuring operations in sure international locations.
Complete loss cited as an distinctive merchandise through the fourth quarter, stood at Rs 3,936 crore.